STOCK TITAN

Aimei Health Technology Co., Ltd. (AFJKU) SEC Filings

AFJKU NASDAQ
Rhea-AI Summary

Aimei Health Technology Co., Ltd. (AFJK) received shareholder approval to extend its business-combination deadline from December 6, 2026, to December 6, 2027, extending the permitted period from up to 36 months to up to 48 months from its IPO. The Articles amendment took effect November 10, 2026; the related Trust Agreement amendment is dated November 19, 2026. The required trust deposit for each monthly extension remains the lesser of $80,000 for all outstanding Public Shares and $0.033 for each outstanding Public Share. The Article and Trust Agreement proposals each received 2,757,268 votes for, 5,377 against and 16 abstentions.

Holders of 841,629 Public Shares exercised redemption rights for cash at approximately $12.33 per share, for approximately $10,377,384 in total. After payment, the Trust Account will have approximately $2,450,031, and the company will have 2,324,703 ordinary shares outstanding.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Aimei Health Technology Co., Ltd. (AFJK) entered into a non-binding letter of intent with Hera Health Solutions Inc. for a proposed business combination. Under the LOI, Aimei would acquire 100% of Hera’s outstanding equity and equity equivalents in exchange for shares of the combined public company.

The LOI is non-binding on the proposed transaction, except for provisions including confidentiality and exclusivity. The transaction remains subject to definitive agreements, due diligence, required regulatory and shareholder approvals, and other customary closing conditions. Aimei expects to provide further details after execution of a definitive business combination agreement. Hera is developing drug-delivery technologies, including biodegradable nanofiber scaffolds and AI-driven formulation capabilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Aimei Health Technology Co., Ltd. (AFJK) deposited $34,330.96 into its trust account for public shareholders, extending its time to complete an initial business combination by one month, from November 6, 2026 to December 6, 2026. This is the 24th extension permitted under its amended and restated articles of association.

To fund the extension payment, the company issued an unsecured promissory note with principal of $34,330.96 to Aimei Investment Ltd. The note bears no interest and is due when the company completes a business combination. Aimei Investment Ltd. may convert all or part of the note into private units at $10.00 per unit immediately before completion, by giving written notice at least two business days before closing. Each unit consists of one ordinary share and a right to receive one-fifth of one ordinary share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.72%
Tags
current report
Rhea-AI Summary

Aimei Health Technology Co., Ltd. (AFJK) seeks approval for Articles and trust-agreement amendments that would extend its business-combination period from 36 to 48 months, moving the deadline from December 6, 2026, to as late as December 6, 2027. If approved, each monthly extension requires the Sponsor to deposit the lesser of $80,000 for all outstanding Public Shares or $0.033 per outstanding Public Share. Shareholders also vote on MaloneBailey, LLP as auditor for the year ending December 31, 2026, and possible adjournment at the November 10, 2026 meeting.

The United Hydrogen transaction was terminated on July 7, 2026, because required China Securities Regulatory Commission approval had not been obtained as of July 6, 2026; AFJK says it is evaluating new targets. Approval of the Articles amendment would trigger an offer to redeem Public Shares; the estimated per-share redemption value was approximately $12.25 per Public Share as of October 2, 2026, with a November 6, 2026 tender deadline.

As of October 2, 2026, the Sponsor, directors, executive officers and affiliates beneficially owned and were entitled to vote 2,057,000 ordinary shares, approximately 64.96% of shares outstanding, and were expected to support all four proposals. The Articles amendment requires two-thirds of votes cast; each other proposal requires a simple majority.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.69%
Tags
proxy
-
Rhea-AI Summary

Aimei Health Technology Co., Ltd. (AFJK) deposited $34,330.96 into its trust account for public shareholders, enabling a one-month extension of its initial business-combination deadline from October 6, 2026 to November 6, 2026. This is the 23rd extension permitted under its amended and restated articles.

To fund the payment, Aimei issued an unsecured, non-interest-bearing promissory note with $34,330.96 principal to Aimei Investment Ltd. The principal is due when Aimei consummates its business combination with United Hydrogen. Aimei Investment may convert all or part of the note into private units at $10.00 per unit immediately before closing, by providing written notice at least two business days before closing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
current report
-
Rhea-AI Summary

Aimei Health Technology Co., Ltd. (AFJK) extended the deadline to complete its initial business combination by one month, making a payment of $34,330.96 into its trust account to move the Termination Date from September 6, 2026 to October 6, 2026. This amount represents the lesser of $80,000 for all outstanding public shares and $0.033 per outstanding public share for the monthly extension and is the 22nd extension permitted under its Amended and Restated Articles of Association.

To fund the extension payment, the company issued an unsecured Promissory Note for $34,330.96 to Aimei Investment Ltd. The note bears no interest and becomes due upon consummation of the planned business combination with United Hydrogen. The payee may convert the note into private units at $10.00 per unit, each unit consisting of one ordinary share and one right to receive one-fifth of one ordinary share, immediately prior to closing by giving two business days’ written notice.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.47%
Tags
current report
Rhea-AI Summary

Aimei Health Technology Co., Ltd. (AFJK) reports that Nasdaq has notified it that its Market Value of Listed Securities (MVLS) has been below $50,000,000 and its Market Value of Publicly Held Shares (MVPHS) has been below $15,000,000 for the last 30 consecutive business days, violating Nasdaq Global Market continued listing standards.

The company has two separate 180-day compliance periods, through February 17, 2027, to have MVLS at or above $50,000,000 and MVPHS at or above $15,000,000 for at least 10 consecutive business days. AFJK’s shares continue to trade on the Nasdaq Global Market, but failure to regain compliance could lead to delisting or a transfer to the Nasdaq Capital Market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
current report
-
Rhea-AI Summary

Aimei Health Technology Co., Ltd., a SPAC focused on healthcare innovation, reported a small net loss of $37,704 for the six months ended June 30, 2026, as general, administrative and operational costs of $254,332 exceeded $216,628 of interest income on cash held in its trust account.

Assets totaled $12.53 million, including $12.49 million in the Trust Account and only $1,466 of operating cash, alongside a working capital deficit of $3.79 million and $2.20 million of related-party extension loans. As of June 30, 2026, 1,040,332 public shares were classified as redeemable at $12.00 per share, with an additional 2,126,000 non-redeemable ordinary shares outstanding.

The company terminated its previously agreed Business Combination Agreement with United Hydrogen on July 7, 2026, so that transaction will not close, and it continues to search for a new target. Management disclosed substantial doubt about the ability to continue as a going concern if no business combination is completed by the extended deadline, and also reported a material weakness in internal controls related to inadequate segregation of duties and insufficient written procedures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
quarterly report
-
Rhea-AI Summary

Aimei Health Technology Co., Ltd. has a significant shareholder group led by First Trust entities. As of April 30, 2026, First Trust Merger Arbitrage Fund (VARBX) held 649,911 Ordinary Shares, representing 20.53% of Aimei’s outstanding Ordinary Shares. First Trust Capital Management L.P. (FTCM), together with First Trust Capital Solutions L.P. (FTCS) and FTCS Sub GP LLC (Sub GP), collectively reported beneficial ownership of 680,000 Ordinary Shares, or 21.48% of the class.

FTCM acts as investment adviser to various client accounts, including VARBX, with authority to purchase, vote and dispose of Aimei shares. FTCS and Sub GP are described as control persons of FTCM and may be deemed beneficial owners of the reported shares, although they do not hold Aimei shares for their own accounts. All reporting persons indicate sole voting and dispositive power over their respective reported holdings, with no shared voting or dispositive power.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
ownership
Rhea-AI Summary

Aimei Health Technology Co., Ltd deposited $34,330.96 into its trust account for public shareholders, equal to the lesser of $80,000 in total or $0.033 per outstanding public share for a monthly extension. This extends the deadline to consummate its initial business combination from August 6, 2026 to September 6, 2026, representing the company’s 21st permitted extension.

To fund this payment, Aimei Health issued an unsecured, non‑interest‑bearing promissory note for $34,330.96 to Aimei Health Ltd, due upon completion of its business combination with United Hydrogen. The payee may convert the note into private units at $10.00 per unit, each unit including one ordinary share and a right to receive one‑fifth of an ordinary share, by giving written notice at least two business days before closing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
current report

FAQ

How many Aimei Health Technology Co., Ltd. (AFJKU) SEC filings are available on StockTitan?

StockTitan tracks 31 SEC filings for Aimei Health Technology Co., Ltd. (AFJKU), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Aimei Health Technology Co., Ltd. (AFJKU)?

The most recent SEC filing for Aimei Health Technology Co., Ltd. (AFJKU) was filed on November 19, 2026.